WASHINGTON — A new “right-to-try” bill hurtling toward a House vote this week would give the Food and Drug Administration some oversight of experimental treatments permitted under a new process, but critics warn that it would still undermine the agency’s role in protecting patients.

The new legislation, from House Energy and Commerce Committee Chairman Greg Walden (R-Ore.), is the latest salvo in the effort to create a new pathway for patients with terminal illness to access experimental therapies. The House of Representatives is set to vote on the measure Tuesday, after which it will head back to the Senate for further consideration.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy